CREB-binding protein and p300: Molecular integrators of hematopoietic transcription

Blood

Volumn 95, Issue 3, 2000, Pages 745-755

  Blobel, Gerd A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ERYTHROID KRUPPEL LIKE FACTOR; PROTEIN P300; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2;

ACETYLATION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; RUBINSTEIN SYNDROME;

EID: 0034141972     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.3.745.003k05_745_755     Document Type: Review

References (167)

1. Sieweke MH, Graf T. A transcription factor party during blood cell differentiation. Curr Opin Genet Dev. 1998;8:545-551.
2. Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood. 1996;87:4025-4039.
3. Petrij F, Giles RH, Dauwerse HG. et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature (London). 1995;376:348-351.
4. Tanaka Y, Naruse I, Maekawa T, Masuya H, Shiroishi T, Ishii S. Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi. Proc Natl Acad Sci USA. 1997;94:10,215-10,220.
5. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM, Yao T-P. Gene dose-dependent control of hematopoietic differentiation and hematologic tumor suppression by CBP. Submitted 1999.
6. Oike Y, Takakura N, Hata A, et al. Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculoangiogenesis. Blood. 1999;93:2771-2779.
7. Eckner R. p300 and CBP as transcriptional regulators and targets of oncogenic events. Biol Chem. 1996;377:685-688.
8. Shikama N, Lyon J, LaThangue NB. The p300/ CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol. 1997;7: 230-236.
9. Giles RH, Peters DJM, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 1998;14:178-183.
10. Chrivia JC, Kwok RPS, Lamb N, Hagiwara M, Montminy MR, Goodman RG. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature (London). 1993;365:855-859.
11. Eckner R, Ewen ME, Newsome D, et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kd protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 1994;8:869-884.
12. Kawasaki H, Eckner R, Yao T, et al. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature. 1998; 393:284-289.
13. Yao T-P, Oh SP, Fuchs M, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell. 1998;93:361-372.
14. Shi Y, Mello C. A CBP/p300 homolog specifies multiple differentiation pathways in Caennorhabditis elegans. Genes Dev. 1997;12:943-955.
15. Kamel Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996; 85:403-414.
16. Horvai AE, Xu L, Korzus E, et al. Nuclear integration of JAK/STAT and RAS/ AP-1 signaling by CBP and p300. Proc Natl Acad Sci U S A. 1997; 94:1074-1079.
17. Akimaru H, Chen Y, Dai P, et al. Drosophila CBP is a co-activator of cubitus interruptus in hedge-hog signalling. Nature (London). 1997;386:735-738.
18. Akimaru H, Hou D-X, Ishii S. Drosophila CBP is required for dorsal-dependent twist expression. Nature (London). 1997;17:211-214.
19. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/ CBP in p53-dependent signal pathways. Cell. 1997;89:1175-1184.
20. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature (London). 1997; 387:823-827.
21. Gu W, Shi X-L, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature (London). 1997;387:819-823.
22. Lee KC, Crowe AJ, Barton MC. p53-mediated repression of alpha-letoprotein gene expression by specitic DNA binding. Mol Cell Biol. 1999;19: 1279-1288.
23. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature (London). 1996;384:641-643.
24. Ogryzko W, Schiltz LR, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases Cell. 1996;87:953-959.
25. Hebbes TR, Clayton AL, Thorne AW, Crane-Robinson C. Core histone hyperacetylation co-maps with generalized DNase I sensitivity in the chicken β-globin chromosomal domain. EMBO J. 1994;13:1823-1830.
26. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription. Cell. 1997;89:325-328.
27. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;90:595-606.
28. Sakaguchi K, Herrera JE, Saito S, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 198;12:2831-2841.
29. Liu L, Scolnick DM, Trievel HC, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol. 1999;19:1202-1209.
30. Waltzer L, Bienz M. Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature (London). 1998;395:521-525.
31. Zhang W, Bieker JJ. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sci U S A. 1998;95:9855-9860.
32. Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. 1998;396:594-598.
33. Hung H-L, Lau J, Weiss MJ, Blobel GA. CREB-Binding Protein (CBP) acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol. 1999;19:3496-3505.
34. Li Q, Herrler M, Landsberger N, et al. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J. 1998; 17:6300-6315.
35. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolfe AP, Ge H. Acetylaticn of general transcription factors by histone acetyltransferases. Current Biol. 1997;7:689-692.
36. Wong J, Patterton D, Imhof A, Guschin D, Shi Y-B, Wolffe AP. Distinct requirements for chromatin assembly in transcriptional repression by thyroid hormone receptor and histone deacetylase. EMBO J. 1998;17:520-534.
37. Munshi N, Merika M, Yie J, Senger K, Chen G, Thanos D. Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell. 1998;2:457-467.
38. Moran E. DNA tumor transforming proteins and the cell cycle. Curr Opin Genet Dev. 1993;
39. Bayley ST, Mymryk JS. Adenovirus E1A proteins and transformation. Int J Oncol. 1994;5:425-444.
40. Weston K. The myb genes. Sem Cancer Biol. 1990;1:371-382.
41. Clarke MF, Kukowska-Latallo JF, Westin E, Smith M, Prochownik E. Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol Cel. Biol. 1988;8:884-892.
42. McMahon J, Howe KM, Watson RJ. The induction of Friend erythroleukemia differentiation is markedly affected by expression of a transfected c-myb cDNA. Oncogene. 1988;3:717-720.
43. Todokoro K, Watson RJ, Higo H, et al. Down-regulation of c-myb gene expression is a prerequisite for erythropoietin-induced erythroid differentiation. Proc Natl Acad Sci U S A. 1988;21:267-272.
44. McClinton D, Stafford J, Brents L, Bender TP, Kuehl WM. Differentiation of mouse erythroleukemia cells is blocked by late up-regulation of a c-myb transgene. Mol Cell Biol. 1990;10:705-710.
45. Yanagisawa H, Nagasawa T, Kuramochi S, Abe T, Ikawa Y, Todokoro K. Constitutuive expression of exogenous c-myb gene causes maturation block in monocyte-macrophage differentiation. Biochim Biophys Acta. 1991;1088:380-384.
46. Weber BL, Westin EH, Clarke MF. Differentiation of mouse erythroleukemia cells is enhanced by alternatively spliced c-myb mRNA. Science. 1990;249:1291-1293.
47. Gewirtz AM, Calabretta B. A c-myb antisense oligonucleatide inhibits normal human hematopoiesis in vitro. Science. 1988;242:1303-1306.
48. Gewirtz AM, Anfossi G, Venturelli D, Valpreda S, Sims R, Calabretta B. G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded byc-myb. Science. 1989;245:180-183.
49. Anfossi G, Gewirtz AM, Calabretta B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci U S A. 1989;86.
50. Mucenski ML, McLain K, Kier AB, et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 1991;65:677-689.
51. Dal P, Akimaru H, Tanaka Y, et al. CBP as a transcriptional coactivator of c-Myb. Genes Dev. 1995;10:528-540.
52. Oelgeschläger M, Janknecht R, Krieg J, Schreek S, Lüscher B. Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific trans-activation and on the cooperativity with NF-M, EMBO J. 1996;15:2771-2780.
53. Hen R, Borrelli E, Chambon P. Repression of the immunoglobulin heavy chain enhancer by the adenovirus-2 E1A products. Science. 1985;230: 1391-1394.
54. Bergman Y, Shavit D. Regulation of the Ig Kappa-chain enhancer by the adenovirus E1A gene products. Repression in lymphoid cells, activation in fibroblasts. J Immunol. 1988;140:2073-2080.
55. Shen C-P, Kadesch T. B-cell-specific transcription by an E47 homodimer. Mol Cell Biol. 1995;15: 4518-4524.
56. Bain G, Maandag ECR, Izon DJ, et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin rearrangements. Cell. 1994;79:885-892.
57. Zhuang Y, Soriano P, Weintraub H: The helix-loop-helix gene E2A is required for B cell formation. Cell. 1994;79:875-884.
58. Zhuang Y, Kim C, Bartelmez S, Cheng P-F, Groudine M, Weintraub H. Helix-loop-helix transcription factors E12 and E47 are not essential for skeletal or cardiac myogenesis, erythropoiesis, chondrogenesis, or neurogenesis. Proc Natl Acad Sci U S A. 1992;89:12,132-12,136.
59. Eckner R, Yao T-P, Oldread E, Livingston DM. Interaction and functional collaboration of p300/ CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev. 1996;10:2478-2490.
60. Pevny L, Simon MC, Robertson E, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature (London). 1991;349:257-260.
61. Pevny L, Lin CS, D'Agati V, Simon MC, Orkin SH, Costantini F. Development of hematopoietic cells lacking transcription factor GATA-1. Development. 1995;121:163-172.
62. Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev. 1994;8:1184-1197.
63. Fujiwara Y, Browne CP, Cunniff K, Goff SC, Orkin SH. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A. 1996;93:12,355-12,358.
64. Weiss MJ, Orkin SH. Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci U S A. 1995;92:9623-9627.
65. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16:3965-3973.
66. Waiss MJ, Yu C, Orkin SH. Erythroid-cell-specific properities of transcription factor GATA-1 revealed by phenotypic rescue of a gene targeted cell line. Mol Cell Biol. 1997;17:1642-1651.
67. Higgs DR. Do LCRs open chromatin domains? Cell. 1998;95:299-302.
68. Blobel GA, Nakajima T, Eckner R, Montminy M, Orkin SH. CREB-bining protein (CBP) cooperates with transcription factor GATA-1 and is required for erythroid differentiation. Proc Natl Acad Sci U S A. 1998;95:2061-2066.
69. Sposi NM, Zon LI, Care A, et al. Cell cycle-dependent initiation and lineage-dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors. Proc Natl Acad Sci U S A. 1992;89:6353-6357.
70. Leonard M, Brice M, Engel JD, Papayannopoulou T Dynamics of GATA transcription factor expression during erythroid differentiation. Blood. 1993; 82:1071-1079.
71. Tsai F-Y, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature (London). 1994;371:221-226.
72. Forsberg EC, Johnson K, Zaboikina TN, Mosser EA, Bresnick EH. Requirement of an E1A-sensitive coactivator for long-range transactivation by the β-globin locus control region. J Biol Chem. 1999;274:26,850-26,859.
73. Andrews N, Erdjument-Bromage H, Davidson M, Tempst P, Orkin SH. Erythroid transcription factor NF-E2 is a hematopoietic-specific basic-leucine zipper protein. Nature (London). 1993;362:722-728.
74. Andrews NC, Kotkow KJ, Ney PA, Erdjument-Bromage H, Tempst P, Orkin SH. The ubiquitous subunit of erythroid transcription factor NF-E2 is a small basic-leucine zipper protein related to the v-maf oncogene. Proc Natl Acad Sci U S A. 1993; 90:11,488-11,492.
75. Igarashi K, Kataoka K, Itoh K, Hayashi N, Nishizawa M, Yamamoto M. Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. Nature (London). 1994; 367:568-572.
76. Blank V, Andrews NC. The maf transcription factors: regulators of differentiation. Trends Biochem Sci. 1997;22:437-441.
77. Kobayashi A, Ito E, Toki T, et al. Molecular cloning and functional characterization of a new Cap'n' Collar family transcription factor Nrf3. J Biol Chem. 1999;274:6443-6452.
78. Shivdasani RA, Rosenblatt MF, Zucker-Franklin DC, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoieitin/MGDF in megakaryocyte development. Cell. 1995;81:695-701.
79. Shivdasani RA, Orkin SH. Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc Natl Acad Sci U S A. 1995;92.
80. Cheng X, Reginato MJ, Andrews NC, Lazar MA. The Transcriptional Integrator CREB- binding protein mediates positive cross talk between nuclear hormone receptors and the hematopoietic bZip protein p45/NF-E2. Mol Cell Biol. 1997; 1:1407-1416.
81. Braverman LE, Utiger RD. The Thyroid: a Fundamental and Clinical Text. 6th ed. Philadelphia. PA: JB Lippincott; 1991.
82. Armstrong JA, Emerson BM. NF-E2 disrupts chromatin structure at human β-globin locus control region hypersensitive site 2 in vitro. Mol Cell Biol. 1996;16:5634-5644.
83. Miller IJ, Bieker JJ. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family of nuclear proteins. Mol Cell Biol. 1993;13: 2776-2786.
84. Perkins AC, Sharpe AH, Orkin SH. Lethal β-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature (London). 1995; 375:318-322.
85. Nuez B, Michalovich D, Bygrave A, Ploemacher R, Grosveld F. Defective haematopoiesis in fetal liver resulting from inactivation of the EKLF gene. Nature (London). 1995;375:316-318.
86. Perkins AC, Gaensler KM, Orkin SH. Silencing of human fetal globin expression is impaired in the absence of the adult beta-globin gene activator protein EKLF. Proc Natl Acad Sci U S A. 1996;93: 12,267-12,271.
87. Wijgerde M, Gribnau J, Trimborn T, et al. The role of EKLF in human β-globin gene competition. Genes Dev. 1996;10:2894-2902.
88. Merika M, Orkin SH. Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with Krüppel family proteins Sp1 and EKLF. Mol Cell Biol. 1995;15:2437-2447.
89. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem. 1998;273: 28,545-28,548.
90. Yamanaka R, Lekstrom-Himes J, Barlow C, Wynshaw-Boris A, Xanthopoulos KG. CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis. Int J Mol Med. 1998;1:213-221.
91. Yamanaka R, Barlow C, Lekstrom-Himes J, et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci U S A. 1997;94:13,187.
92. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A. 1997;94:569-574.
93. Screpanti I, Romani L, Musiani P, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J. 1995;14:1932-1941.
94. Tanaka T, Akira S, Yoshida K, et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell. 1995;80:353-361.
95. Poll V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem. 1998;45:29,279-29,282.
96. Mink S, Haenig B, Klempnauer KH. Interaction and functional collaboration of p300 and C/EBPβ. Mol Cell Biol. 1997;17:6609-6617.
97. Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem. 1993;211: 7-18.
98. Metz T, Gral T. v-myb and v-ets transform chicken erythroid cells and cooperate in trans and in cis to induce distinct differentiation phenotypes. Genes Dev. 1991;5:369-380.
99. Metz T, Graf T. Fusion of the nuclear oncoproteins v-Myb and v-Ets is required for the leukemogenicity of E26 virus. Cell. 1991;66:95-105.
100. Bories J-C, Willerford DM, Grevin D, et al. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature (London). 1995;377:635-638.
101. Muthusamy N, Barton K, Leiden JM. Defective activation and survival of T cells lacking the Ets-1 transcription factor. Nature (London). 1995;377: 639-642.
102. Wasylyk B, Wasylyk C. Flores P, Begue A, Leprince D, Stehelin D. The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature (London). 1990;346:191-193.
103. Dudek H, Tantravahi RV, Rao VN, Reddy ES, Reddy EP. Myb and Ets proteins cooperate in transcriptional activation of the mim-1 promoter. Proc Natl Acad Sci U S A. 1992;89:1291-1295.
104. Sharpiro LH. Myb and Ets proteins cooperate to transactivate an early myeloid gene. J Biol Chem. 1995;270:8763-8771.
105. Postigo AA, Sheppard AM, Mucenski ML, Dean DC. c-Myb and Ets proteins synergize to overcome transcriptional repression by ZEB. EMBO J. 1997;16:3924-3934.
106. Ratajczak MZ, Perrotti D, Melotti P, et al. Myb and Ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. Blood. 1998;91:1934-1946.
107. Lemarchandel V, Ghysdael J, Mignotte V, Rahuel C, Romeo PH. GATA and ETS cis-acting sequences mediate megakaryocyte-specific gene expression. Mol Cell Biol. 1993;13:668-676.
108. Bastian LS, Yagi M, Chan C, Roth GJ. Analysis of the megakaryocyte glycoprotein IX promoter identifies positive and negative regulatory domains and functional GATA and Ets sites. J Biochem. 1996;271:18,554-18,560.
109. Hashimoto Y, Ware J. Identification of essential GATA and Ets binding motifs within the promoter of the platelet glycopretein Ib alpha gene. J Biochem. 1995;270:24,532-24,539.
110. Deveaux S, Filipe A, Lemarchandel V, Ghysdael J, Romeo PH, Mignotte V. Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood. 1996;87: 4678-4685.
111. Minami T, Tachibana K, Imanishi T, Doi T. Both Ets-1 and GATA-1 are essential for positive regulation of platelet factor 4 gene expression. Eur J Biochem. 1998;258:879-889.
112. Yang C, Shapiro LH, Rivera M, Kumar A, Brindle PK. A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions. Mol Cell Biol. 1998;18:2218-2229.
113. Yamamoto H, Kihara-Negishi F, Yamada T, Hashimoto Y, Oikawa T. Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP Oncogene. 1999; 18:1495-1501.
114. Hromas R, Orazi A, Neiman RS, et al. Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. Blood. 1993;82:2998-3004.
115. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 1998;17:2994-3004.
116. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278: 1059-1064.
117. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
118. Sasaki K, Yagi H, Bronson RT, et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc Natl Acad Sci U S A. 1996;93:12,359-12,363.
119. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA, Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996;93: 3444-3449.
120. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996;87:697-708.
121. Niki M, Okada H, Takano H, et al. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding sub-unit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. Proc Natl Acad Sci U S A. 197;94:5697-5702.
122. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8:21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A. 1998;95:10,860-10,865.
123. Lutterbach B, Westendorf JJ, Linggi B, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol. 1998;18:7176-7184.
124. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18:7185-7191.
125. Hernandez-Munain C, Krangel MS. Regulation of the T-cell receptor delta enhancer by functional cooperation between c-Myb and core-binding factors. Mol Cell Biol. 1994;14:473-483.
126. Britos-Bray M, Friedman AD. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol Cell Biol. 1997;17:5127-5135.
127. Zhang DE, Hetherington CJ, Meyers S, et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol. 1996;16:1231-1240.
128. Hernandez-Munain C, Krangel MS. c-Myb and core-binding factor/PEBP2 display functional synergy but bind independently to adjacent sites in the T-cell receptor delta enhancer. Mol Cell Biol. 1995;15:3090-3099.
129. Rubinstein JH, Taybi H. Broad thumbs and toes and facial abnormalities: a possible mental retardation syndrome. Am J Dis Child. 1963;105:588-608.
130. Miller RW, Rubinstein JH. Tumors in Rubinstein-Taybi syndrome. Am J Med Gen. 1995;56:112-115.
131. Borrow J, Stanton VPJ, Andresen JM, et al. The translocation t(8; 16)(p11; 13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nature Genet. 1996;14: 33-41.
132. Giles RH, Dauwerse JG, Higgins C, et al. Detection of CBP rearrangements in acute myelogenous leukemia with t(8; 16). Leukemia. 1997;11: 2087-2096.
133. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL Nature Genet. 1998;18: 126-135.
134. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (London). 1998;391:815-818.
135. Lin RJ, Nagy L, Inoue S, Shao W, Miller WHJ, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (London). 1998;391:811-814.
136. Taki T, Sako M, Tsuchida M, Hayashi Y. The t(11; 16)(q2313.3) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood. 1997;89:3945-3950.
137. Sobulo OM, Borrow J, Tomek R, et al. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a 1(11;16)(q23;p13.3). Proc Natl Acad Sci U S A. 1997;94:8732-8737.
138. Rowley JD, Reshmi S, Sobulo O, et al. All patients with the T(11;16) (q23: p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997;90:535-541.
139. Satake N, Ishida Y, Otoh Y, et al. Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation. Genes, Chromosomes Cancer. 1997;20:60-63.
140. Ida K, Kitabayashi I, Taki T, et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with 1(11,22)(q23:q13). Blood. 1997;90:4699-4704.
141. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nature Genet. 1992;2:113-118.
142. Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell. 1992;71:701-708.
143. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992;71:691-700.
144. Carey M. The enhanceosome and transcriptional synergy. Cell. 1998;92:5-8.
145. Yang X-J, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature (London). 1996;382:319-324.
146. Chen H, Lin RJ, Schiltz RL, et al. Nuclear receptor Coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997; 90:569-580.
147. Spencer TE, Jenster G, Burcin MM, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (London). 1997;389:194-198.
148. Chang T-J, Scher BM, Waxman S, Scher W. Inhibition of mouse GATA-1 function by the glucocorticoid receptor: possible mechanism of steroid inhibition of erythroleukemia cell differentiation. Mol Endocrinol. 1993; 7:528-542.
149. Blobel GA, Sieff CA, Orkin SH. Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Mol Cell Biol. 1995;15:3147-3153.
150. Blobel GA, Orkin SH. Estrogen-induced apoptosis by inhibition of the erythroid transcription factor GATA-1. Mol Cell Biol. 1996;16:1687-1694.
151. Kwok RP, Lunblad JR, Chrivia JC, et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature (London). 1994;370:223-226.
152. Abraham SE, Lobo S, Yaciuk P, Wang HG, Moran E. p300, and p300-associated proteins, are components of TATA-binding protein (TBP) complexes. Oncogene. 1993;8:1639-1647.
153. Swope DL, Mueller CL, Chrivia JC. CREB-binding protein activates transcription through multiple domains. J Biol Chem. 1996;271:28,138-28,145.
154. Dallas PB, Yaciuk P, Moran E. Characterization of monoclonal antibodies raised against p300: both p300 and CBP are present in intracellular TBP complexes. J Virol. 1997;71:1726-1731.
155. Sang N, Avantaggiati ML, Giordano A. Roles of p300, pocket proteins, and hTBP in E1A-mediated transcriptional regulation and inhibition of p53 transactivation activity. J Cell Biochem. 1997; 66:277-285.
156. Kee B, Arias J, Montminy M. Adaptor mediated recruitment of RNA polymerase II to a signal dependent activator. J Biol Chem. 1996;271:2373-2375.
157. Nakajima T, Uchida C, Anderson SF, Parvin JD, Montminy M. Analysis of a cAMP-responsive activator reveals a two-component mechanism for transcriptional induction via signal-dependent factors. Genes Dev. 1997;11:738-747.
158. Nakajima T, Uchida C, Anderson SF, et al. RNA helicase A mediates association of CBP with RN A polymerase II. Cell. 1997;90:1107-1112.
159. Cho H, Orphanides G, Sun X, et al. A human RNA polymerase II complex containing factors that modify chromatin structure. Mol Cell Biol. 1998; 18:5355-5363.
160. Neish AS, Anderson SF, Schlegel BP, Wei W, Parvin JD. Factors associated with the mammalian RNA polymerase II holoenzyme. Nucleic Acids Res. 1998;26:847-853.
161. Korzus E, Torchia J, Rose DW, et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science. 1998;279:703-707.
162. Boyes J, Omichinsky J, Clark D, Pikaart M, Felsenfeld G. Perturbation of nucleosome structure by the erythroid transcription factor GATA-1. J Mol Biol 1998;279:529-544.
163. Kadonaga JT. Eukaryotic transcription: an interlaced network of transcription factors and chromatin-modifying machines. Cell. 1998;92:307-313.
164. Armstrong JA, Bieker JJ, Emerson BM. A SWI/ SNF-related chromatin remodeling complex, E-RC1, is required for tissue-specific transcriptional regulation by EKLF in vitro. Cell. 1998;95: 93-104.
165. Chen WY, Bailey EC, McCune SL, Dong J-Y, Townes TM. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci U S A. 1997;94: 5798-5803.
166. Darkin-Rattray SJ, Gurnett AM, Myers RW, et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci U S A. 1996;93:13,143-13,147.
167. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou M-M. Structure and ligand of a histone acetyltransferase bromodomain. Nature (London). 1999;399:491-496.